Bioartificial liver and liver transplantation: new modalities for the treatment of liver failure
-
摘要: 肝衰竭的主要特征是肝细胞大范围坏死,病情进展迅速且预后差,目前治疗缺乏特效药物和手段。归纳了肝衰竭的4种治疗手段:内科治疗、细胞移植、肝移植和人工肝支持治疗,并就现有的治疗手段进行阐述分析。目前内科治疗方案有待优化,细胞移植治疗尚未应用于临床,肝移植是最有效的手段,但供肝短缺、费用昂贵,人工肝可以有效清除患者体内毒性物质。因此提出人工肝作为肝移植的过渡治疗,可以为肝再生或者肝移植争取时间,延长患者生存期,具有良好的应用前景。生物人工肝联合肝移植的新模式,可以为肝衰竭患者带来福音。Abstract: The main features of liver failure are extensive necrosis of hepatocytes, rapid disease progression, and poor prognosis, and at present, there are no effective drugs and methods for the treatment of liver failure. This article summarizes four treatment methods for liver failure, i. e., medical treatment, cell transplantation, liver transplantation, and artificial liver support therapy, and elaborates on the existing treatment methods. The current medical treatment regimen should be optimized; cell transplantation has not been used in clinical practice; liver transplantation is the most effective method, but it is limited by donor liver shortage and high costs; artificial liver can effectively remove toxic substances in human body. Therefore, this article puts forward artificial liver as a transition for liver transplantation; artificial liver can buy time for liver regeneration or liver transplantation and prolong patients'survival time and thus has a promising future. The new treatment modality of bioartificial liver combined with liver transplantation may bring good news to patients with liver failure.
-
Key words:
- liver failure /
- liver transplantation /
- liver, artificial /
- therapy
-
[1]NEVENS F, LALEMAN W.Artificial liver support devices as treatment option for liver failure[J].Best Pract Res Clin Gastroenterol, 2012, 26 (1) :17-26. [2] Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, CMA;Severe Liver Diseases and Artificial Liver Group, Chinese Society of Hepatology, CMA.Diagnostic and treatment guidelines for liver failure (2012 version) [J].Chin J Clin Infect Dis, 2012, 5 (6) :321-327. (in Chinese) 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南 (2012年版) [J].中华临床感染病杂志, 2012, 5 (6) :321-327. [3]SARIN SK, KEDARISETTY CK, ABBAS Z, et al.Acute-onchronic liver failure:consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014[J].Hepatol Int, 2014, 8 (4) :453-471. [4]Drug-induced Liver Disease Study Group, Chinese Society of Hepatology, Chinese Medical Association.Guidelines for the management of drug-induced liver injury[J].J Clin Hepatol, 2015, 31 (11) :1752-1769. (in Chinese) 中华医学会肝病学分会药物性肝病学组.药物性肝损伤诊治指南[J].临床肝胆病杂志, 2015, 31 (11) :1752-1769. [5]YANG YG.Clinical effect of adefovir dipivoxil combined with thymosinα1 in treatment of chronic hepatitis B[J].China Prac Med, 2013, 8 (11) :142-143. (in Chinese) 杨玉贵.阿德福韦酯联合胸腺肽α1治疗慢性乙型病毒性肝炎效果观察[J].中国实用医药, 2013, 8 (11) :142-143. [6]LI L, NING GX, SUN MH, et al.Effects of multi disciplinary team management model on the short-term prognosis of patients with liver failure[J].Chin J Med Guide, 2016, 18 (2) :211-212. (in Chinese) 李力, 宁更献, 孙梅花, 等.多学科团队管理模式对肝功能衰竭患者近期预后的影响[J].中国医药导刊, 2016, 18 (2) :211-212. [7]QIN G, SHAO JG, WANG B, et al.Artificial liver support system improves short-and long-term outcomes of patients with HBV-associated acute-on-chronic liver failure:a single-center experience[J].Medicine (Baltimore) , 2014, 93 (28) :e338. [8]SATO Y, ARAKI H, KATO J, et al.Human mesenchymal stem cells xenografted directly to rat liver are differentiated into human hepatocytes without fusion[J].Blood, 2005, 106 (2) :756-763. [9]FRANCOIS S, MOUISEDDINE M, ALLENET-LEPAGE B, et al.Human mesenchymal stem cells provide protection against radiation-induced liver injury by antioxidative process, vasculature protection, hepatocyte differentiation, and trophic effects[J].Biochem Cell Biol, 2013, 2013:151679. [10]JIN G, QIU G, WU D, et al.Allogeneic bone marrow-derived mesenchymal stem cells attenuate hepatic ischemia-reperfusion injury by suppressing oxidative stress and inhibiting apoptosis in rats[J].Int J Mol Med, 2013, 31 (6) :1395-1401. [11]ZHU X, HE B, ZHOU X, et al.Effects of transplanted bonemarrow-derived mesenchymal stem cells in animal models of acute hepatitis[J].Cell Tissue Res, 2013, 35 (3) :477-486. [12]AYATOLLAHI M, HESAMI Z, JAMSHIDZADEH A, et al.Antioxidant effects of bone marrow mesenchymal stem cell against carbon tetrachloride-induced oxidative damage in rat livers[J].Int J Organ Transplant Med, 2014, 5 (4) :166-173. [13]MOUGIAKAKOS D, JITSCHIN R, JOHANSSON CC, et al.The impact of inflammatory licensing on heme oxygenase-1-mediated induction of regulatory T cells by human mesenchymal stem cells[J].Blood, 2011, 117 (18) :4826-4835. [14]ROCCO F, IUS P, MIRONE S, et al.Ten-year experience with cryopreserved aortic allografts in the surgical treatment of aortic valve pathologies[J].Ital Heart J, 2004, 5 (7) :541-547. [15]LIANG TB, TANG XF, WANG WL, et al.The preliminary clinical experience on ABO-incompatible liver transplantation[J].Chin J Gen Surg, 2006, 21 (6) :399-401. (in Chinese) 梁廷波, 汤晓锋, 王伟林, 等.肝移植中应用ABO血型不合供肝的初步经验[J].中华普通外科杂志, 2006, 21 (6) :399-401. [16]ZHANG WY, DENG YL, HOU JC, et al.Single center's experience of ABO-incompatible liver transplantation in 20 cases[J].Chin J Gen Surg, 2012, 27 (8) :609-611. (in Chinese) 张玮晔, 邓永林, 侯建存, 等.ABO血型不合肝移植20例单中心经验[J].中华普通外科杂志, 2012, 27 (8) :609-611. [17]SHEN ZY, DENG YL, ZHENG H, et al.Clinical retrospective analysis and comprehensive evaluation of ABO-incompatible liver transplantation[J].Chin J Organ Transplant, 2014, 35 (12) :728-731. (in Chinese) 沈中阳, 邓永林, 郑虹, 等.ABO血型不相容肝移植的疗效分析及综合评价[J].中华器官移植杂志, 2014, 35 (12) :728-731. [18]CHERQUI D, SOUBRANE O, HUSSON E, et al.Laparoscopic living donor hepatectomy for liver transplantation in children[J].Lancet, 2002, 359 (9304) :392-396. [19]DETHLOFF T, TOFTENG F, FREDERIKSEN HJ, et al.Effect of prometheus liver assist system on systemic hemodynamics in patients with cirrhosis:a randomized controlled study[J].World J Gastroenterol, 2008, 14 (13) :2065-2071. [20]TAO KS, LI X, DOU KF.The history and development of liver xenotransplantation[J].Ogran Transplantation, 2017, 8 (2) :85-88. (in Chinese) 陶开山, 李霄, 窦科峰.异种肝移植的历史与发展[J].器官移植, 2017, 8 (2) :85-88. [21]ZHANG Y, SHI XL, HAN B, et al.Immunosafety evaluation of a multilayer flat-plate bioartificial liver[J].Am J Med Sci, 2012, 343 (6) :429-434. [22]SHI XL, HAN B, TAN JJ, et al.Factors influencing the transfer of porcine endogenous retroviruses across the membrane in bioartificial livers[J].Int J Artif Organs, 2012, 35 (5) :385-391. [23]HAN B, SHI XL, ZHANG Y, et al.Microbiological safety of a novel bio-artificial liver support system based on porcine hepatocytes:a experimental study[J].Eur J Cancer, 2012, 17:13. [24]ENOSAWA S, SUZUKI S, KAKEFUDA T, et al.Examination of 7-ethoxycoumarin deethylation and ammonia removal activities in 31hepatocyte cell lines[J].Cell Transplantation, 1996, 5 (5) :s39-s40. [25]WERNER A, DUVAR S, MTHING J, et al.Cultivation of immortalized human hepatocytes Hep Z on macroporous Culti Spher Gmicrocarriers[J].Biotechnol Bioeng, 2000, 68 (1) :59-70. [26]POYCK PP, van WIJK AC, van der HOEVEN TV, et al.Evaluation of a new immortalized human fetal liver cell line (c BAL111) for application in bioartificial liver[J].J Hepatol, 2008, 48 (2) :266-275. [27]SAKIYAMA R, BLAU BJ, MIKI T.Clinical translation of bioartificial liver support systems with human pluripotent stem cell-derived hepatic cells[J].World J Gastroenterol, 2017, 23 (11) :1974-1979. [28]OERTEL M, MENTHENA A, CHEN YQ, et al.Properties of cryopreserved fetal liver stem/progenitor cells that exhibit long-term repopulation of the normal rat liver[J].Stem Cells, 2006, 24 (10) :2244-2251. [29]GU J, SHI X, ZHANG Y, et al.Heterotypic interactions in the preservation of morphology and functionality of porcine hepatocytes by bone marrow mesenchymal stem cells in vitro[J].J Cell Physiol, 2009, 219 (1) :100-108. [30]SALERNO S, CAMPANA C, MORELLI S, et al.Human hepatocytes and endothelial cells in organotypic membrane systems[J].Biomaterials, 2011, 32 (34) :8848-8859. [31]SHI XL, GAO Y, YAN Y, et al.Improved survival of porcine acute liver failure by a bioartificial liver device implanted with induced human functional hepatocytes[J].Cell Res, 2016, 26 (2) :206-216. [32]HUANG P, ZHANG L, GAO Y, et al.Direct reprogramming of human fibroblasts to functional and expandable hepatocytes[J].Cell Stem Cell, 2014, 14 (3) :370-384. [33]MIYAZAWA M, TORII T, TOSHIMITSU Y, et al.Hepatocyte dynamics in a three-dimensional rotating bioreactor[J].J Gastroenterol Hepatol, 2007, 22 (11) :1959-1964. [34]CHU XH, SHI XL, FENG ZQ, et al.Chitosan nanofiber scaffold enhances hepatocyte adhesion and function[J].Biotechnol Lett, 2009, 31 (3) :347-352. [35]SHI XL, CHU XH, GU JY, et al.Enhanced oxygen delivery to primary hepatocytes within a multi-layer flat plate bioreactor via red blood cells[J].Chin J Hepatobiliary Surg, 2010, 16 (8) :608-611. (in Chinese) 施晓雷, 褚薛慧, 顾劲扬, 等.红细胞携氧促进多层平板型生物反应器中肝细胞氧供[J].中华肝胆外科杂志, 2010, 16 (8) :608-611. [36]SHI XL, HAN B, ZHENG YS, et al.Primary clinical study of a novel multi-layer flat-plate bioartificiai liver for patients with liver failure[J].Chin J Organ Transplant, 2012, 33 (4) :212-216. (in Chinese) 施晓雷, 韩冰, 郑以山, 等.新型多层平板型生物人工肝体外支持系统治疗肝功能衰竭的临床研究[J].中华器官移植杂志, 2012, 33 (4) :212-216. [37]PAN C, PAN F, SU YZ, et al.Application of non-bioartificial liver in liver transplantation in severe hepatitis patients:a report of9 cases[J].Chin J Organ Transplant, 2005, 26 (7) :423-424. (in Chinese) 潘晨, 潘凡, 苏怡洲, 等.非生物型人工肝在肝移植中的应用九例[J].中华器官移植杂志, 2005, 26 (7) :423-424. [38]JIANG T, CHEN G, JIANG WW.Artificial liver support system used in the perioperative period of liver transplantation[J].J Clin Rehabilit Tissue Engineering Res, 2009, 31 (13) :6125-6128. (in Chinese) 姜涛, 陈刚, 姜炜炜.肝移植围手术期中的人工肝支持[J].中国组织工程研究与临床康复, 2009, 31 (13) :6125-6128.
本文二维码
计量
- 文章访问数: 549
- HTML全文浏览量: 15
- PDF下载量: 251
- 被引次数: 0